We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
+65.28%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$274M
AUM Growth
+$75.2M
Cap. Flow
-$24.8M
Cap. Flow %
-9.07%
Top 10 Hldgs %
99.7%
Holding
11
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$5

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$23.4M
2
PCVX icon
Vaxcyte
PCVX
+$1.42M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$172M 62.95%
765,895
-115,563
-13% -$23.4M
RLYB icon
2
Rallybio
RLYB
$86.7M
$32.9M 12.01%
283,914
– –
PCVX icon
3
Vaxcyte
PCVX
$8.91B
$18.6M 6.81%
776,039
-56,127
-7% -$1.42M
AKUS
4
DELISTED
Akouos Inc
AKUS
$12.1M 4.43%
1,794,088
– –
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.28B
$10.9M 3.97%
569,041
– –
INZY
6
DELISTED
Inozyme Pharma
INZY
$7.13M 2.61%
2,661,154
– –
EXAI
7
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$6.34M 2.32%
772,285
– –
VIGL
8
DELISTED
Vigil Neuroscience
VIGL
$5.1M 1.86%
560,595
– –
FUSN
9
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$4.7M 1.72%
1,560,984
+2
+0% +$5
BOLT icon
10
Bolt Biotherapeutics
BOLT
$6.61M
$2.8M 1.02%
94,573
– –
ALGS icon
11
Aligos Therapeutics
ALGS
$42.5M
$818K 0.3%
29,729
– –

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q3 2022 Portfolio in Review

As of Q3 2022, Pivotal bioVenture Partners Investment Advisor held 11 positions worth $274M, up 38% from $199M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pivotal bioVenture Partners Investment Advisor withdrew a net $24.8M in Q3 2022, reducing 2 holdings. Its largest reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $23.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Pivotal bioVenture Partners Investment Advisor added an estimated $5 to Fusion Pharmaceuticals Inc. Common Shares.

  • Pivotal bioVenture Partners Investment Advisor added most to Fusion Pharmaceuticals Inc. Common Shares in Q3 2022, an estimated $5 increase.
  • Pivotal bioVenture Partners Investment Advisor's biggest Q3 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $23.4M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 100% of its $274M portfolio in Q3 2022.
  • Pivotal bioVenture Partners Investment Advisor opened 0 new positions and closed 0 in Q3 2022.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value rose 38% quarter-over-quarter to $274M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q3 2022, filed 10 Nov 2022.